HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health is seeking applications under the HEAL Initiative to support the preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. Funded activities must accelerate the advancement of early-stage therapeutic candidates toward clinical readiness, spanning lead optimization, IND-enabling studies, biomarker development, and Phase I clinical testing. This milestone-driven program utilizes a phased UG3/UH3 cooperative agreement requiring applicants to possess a promising lead candidate, established assays, and a strong biological rationale for active NIH oversight and collaborative research monitoring. Applications are being accepted through February 20, 2029, under an estimated total program funding of $11,000,000 to support approximately three awards, and inquiries can be directed to PTDP@ninds.nih.gov.
Eligible Applicants
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.